Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Jentzen

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
Physics in Medicine and Biology|April 3, 2010
Experimental investigation of factors affecting the absolute recovery coefficients in iodine-124 PET lesion imagingWalter Jentzen
Journal of Nuclear Medicine Technology|February 7, 2015
An improved iterative thresholding method to delineate PET volumes using the delineation-averaged signal instead of the enclosed maximum signalWalter Jentzen
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 11, 2015
Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124IWalter Jentzen, Andreas Bockisch, Marcus Ruhlmann
European Journal of Nuclear Medicine and Molecular Imaging|August 16, 2006
(124)I in PET imaging: impact on quantification, radiopharmaceutical development and distributionAndreas Bockisch, Lutz Freudenberg, Sandra Rosenbaum, et al.
Inorganic Chemistry|June 9, 2016
Metalloporphines: Dimers and TrimersWalter Jentzen, John A Shelnutt, W Robert Scheidt
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2017
Iodine Symporter Targeting with <sup>124</sup>I/<sup>131</sup>I TheranosticsJames Nagarajah, Marcel Janssen, Philipp Hetkamp, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 28, 2009
A novel view on dosimetry-related radionuclide therapy: presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinomaAlexander R Stahl, Lutz Freudenberg, Andreas Bockisch, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 21, 2007
Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PETLutz S Freudenberg, Walter Jentzen, Stefan P Müller, et al.
Thyroid : Official Journal of the American Thyroid Association|October 18, 2016
Serum Thyroglobulin Doubling Time in Progressive Thyroid CancerRonja Maria Rössing, Walter Jentzen, James Nagarajah, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2017
Fixed 3.7-GBq <sup>131</sup>I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and HistoryWalter Jentzen, Alan E Nahum, Andreas Bockisch, et al.
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
Physics in Medicine and Biology|April 3, 2010
Experimental investigation of factors affecting the absolute recovery coefficients in iodine-124 PET lesion imagingWalter Jentzen
Journal of Nuclear Medicine Technology|February 7, 2015
An improved iterative thresholding method to delineate PET volumes using the delineation-averaged signal instead of the enclosed maximum signalWalter Jentzen
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 11, 2015
Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124IWalter Jentzen, Andreas Bockisch, Marcus Ruhlmann
European Journal of Nuclear Medicine and Molecular Imaging|August 16, 2006
(124)I in PET imaging: impact on quantification, radiopharmaceutical development and distributionAndreas Bockisch, Lutz Freudenberg, Sandra Rosenbaum, et al.
Inorganic Chemistry|June 9, 2016
Metalloporphines: Dimers and TrimersWalter Jentzen, John A Shelnutt, W Robert Scheidt
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2017
Iodine Symporter Targeting with <sup>124</sup>I/<sup>131</sup>I TheranosticsJames Nagarajah, Marcel Janssen, Philipp Hetkamp, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 28, 2009
A novel view on dosimetry-related radionuclide therapy: presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinomaAlexander R Stahl, Lutz Freudenberg, Andreas Bockisch, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 21, 2007
Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PETLutz S Freudenberg, Walter Jentzen, Stefan P Müller, et al.
Thyroid : Official Journal of the American Thyroid Association|October 18, 2016
Serum Thyroglobulin Doubling Time in Progressive Thyroid CancerRonja Maria Rössing, Walter Jentzen, James Nagarajah, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2017
Fixed 3.7-GBq <sup>131</sup>I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and HistoryWalter Jentzen, Alan E Nahum, Andreas Bockisch, et al.
Pageof 9